Vascular adhesive protein-1 (VAP-1) and its role in modeling of inflammation and fibrosis. Nephrology vector
Abstract
There is the whole proteins family, localized on cellular surfaces and regulating lymphocyte-endoteliocyte interaction process, called ekto-peptides. VAP-1 (vascular adhesive protein-1) also belongs to it. Human VAP-1 is the dimeric membrane protein with molecular weight of 180 kD consisting of short N-trailer cytoplasmatic tail, transmembrane domain and most extracellular part. VAP-1 stimulates lymphocytes rolling, adhesion and transmigration through endothelial vessels lining, and also polymorphic and nuclear leukocytes. During studying of VAP-1 expression in kidneys, it is found in peritubular capillaries and perithelial cells of the, and also in smooth muscle cells of larger vessels. Almost completely absent is VAP-1 expression in glomerular endothelial cells.Further studying of signal VAP-1-mediated pathway influence on glomerulonephritis course and outcomes will provide to expand ideas of disease pathogenesis and new influence ways on chronic kidney disease progressing.
About the Authors
M. M. Batiushin
Rostov State Medical University
Russian Federation
Russian Federation
H. Z. Gadaborsheva
Rostov State Medical University
Russian Federation
Russian Federation
References
1. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992; 257· 1407-1409
2. Rucker RB, O’Dell BL. Connective tissue amine oxidase I. Purification of bovine aorta amine oxidase and its comparison with plasma amine oxidase. Biochim Biophys Acta Enzymol 1971; 235·32-43
3. Airenne TT, Nymalm X Kidron H et al. Crystal structure of the human vascular adhesion protein-1· Unique structural features with functional implications. Protein Science 2005; 14·1964-1974.
4. Jalkanen S, Salmi M. Cell surface monoamine oxidases· enzymes in search of a function. EMBO J. 2001; 20· 3893-3901
5. Abella A, Garcia-Vicente S, Viguerie N et al. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 2004; 47· 429-438
6. Kurkijarvi R, Adams DH, Leino R et al. Circulating form of human vascular adhesion protein-1 (VAP-1)· increased serum levels in inflammatory liver diseases. J Immunol 1998; 161· 1549-1557
7. Salmi M, Jalkanen S. Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood. 2006; 108· 1555-1561
8. Tohka S, Laukkanen M-L, Jalkanen S, Salmi M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates their recruitment in vivo. FASEB J. 2001; 15· 373-382
9. Salmi M, Yegutkin GG, Lehvonen R et al. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 2001; 14· 265-276
10. Dunkel P, Balogh B, Meleddu R et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1· a patent survey. Expert Opin. Ther. Patents 2011; 21(9)· 1453-1471
11. Kinemuchi H, Sugimoto H, Obata T, Satoh N, Ueda S. Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues. Neurotoxicology. 2004; 25· 325-335
12. Merinen M, Irjala H, Salmi M et al. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol. 2005; 166· 793-800
13. Koskinen K, Vainio PJ, Smith DJ et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004; 103· 3388-3395
14. Noonan T, Lukas S, Peet GW et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am. J. Clin. Exp. Immunol. 2013; 2(2)· 172-185
15. Galkina E, Ley K. Vascular Adhesion Molecules in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27· 2292-2301
16. Jalkanen S, Karikoski M, Mercier N et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood. 2007; 110· 1864 -1870
17. Morin N, Lizcano JM, Fontana E et al. Semicarbazide-sensitive amineoxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 2001; 297· 563-572
18. Carpene C, Bour S, Visentin V et al. Amine oxidase substrates for impaired glucose tolerance correction. J Physiol Biochem 2005; 61· 405-420
19. Iffiu-Soltesz Z, Wanecq E, Lomba A et al. Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res 2010; 61· 355-363
20. Mercader J, Iffiu-Soltesz Z, Brenachot X et al. SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future MedChem 2010; 2· 1735-1749
21. Noda K, She H, Nakazawa T et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 2008; 22· 2928-2935
22. Kurkijärvi R, Jalkanen S, Isoniemi H, Salmi M. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur. J. Immunol. 2001. 31· 2876-2884
23. Boomsma F, Veldhuisen DJ van, Kam PJ et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997; 33· 387-391
24. Airas L, Mikkola J, Vainio JM et al. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. J of Neuroimmunology 2006; 177· 132-135
25. Koc-Zorawska E, Malyszko J, Zbroch E et al. Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Arch Med Sci 2012; 8(6)· 1048-1052
26. Koc-Zorawska E, Malyszko J, Zbroch E et al. VAP-1 in peritoneally dialyzed patients. Postepy Hig Med Dosw (Online). 2013; 67· 1340-134
27. Lin M-S, Li H-Y Wei J-N et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clinical Biochemistry 2008; (41)· 1362-1367
28. Lin S., Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173· 1617-1627
29. Kawakami T, Mimura I, Shoji K et al. Hypoxia and fibrosis in chronic kidney disease· crossing at pericytes. Kidney Int Suppl 2014; (4)· 107-112
30. Epstein FH. Oxygen and renal metabolism. Kidney Int 1997;51· 381-385
31. Lin SL, Chang FC, Schrimpf C et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol. 2011; 178·911-923
32. Schrimpf C, Teebken OE, Wilhelmi M, Duffield JS. The Role of Pericyte Detachment in Vascular Rarefaction. J Vasc Res 2014; 51· 247-258
33. Nakao S, Noda K, Zandi S et al. VAP-1-Mediated M2 Macrophage Infiltration Underlies IL-1 β - but Not VEGF-A-Induced Lymph- and Angiogenesis. Am J Pathol 2011; 178· 1913-1921
34. Foot JS, Yow TT, Schilter H et al. PXS-4681A, a Potent and Selective Mechanism-Based Inhibitor of SSAO/VAP-1 with Anti-Inflammatory Effects In Vivo. J Pharmacol Exp Ther 2013; 347· 365-374
Review
For citations:
Batiushin M.M., Gadaborsheva H.Z. Vascular adhesive protein-1 (VAP-1) and its role in modeling of inflammation and fibrosis. Nephrology vector. Nephrology (Saint-Petersburg). 2015;19(5):23-27. (In Russ.)
Views:
489
Email this article 